Avalanche Biotechnologies Closes Transaction With Annapurna Therapeutics

Avalanche Biotechnologies, Inc. (AAVL) today announced the closing of the previously announced transaction with Annapurna Therapeutics.  “The new management team is focused on applying our extensive clinical development expertise to advance the company’s gene therapy programs into the clinic.  We intend on dosing our first patients for A1AT deficiency by the end of this year and for HAE in 2017 with the goal of generating meaningful human clinical data in the next 24 months,”  said Paul Cleveland, CEO of the now combined company, Adverum Biotechnologies.

Adverum is a gene therapy company committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or diseases of the eye, who currently have limited or burdensome treatment options. Adverum has a robust pipeline and is leveraging its next-generation adeno-associated virus (AAV)-based directed evolution platform to generate product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Our focus on the patient is supported by clinical development expertise and core capabilities in vector optimization, process development, manufacturing, and assay development. For more information, please visit www.adverumbio.com.

Read the entire article here.